Evofem Biosciences Inc

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- Net product sales more than doubled in 2022 vs. prior year -- -- Reduced total operating expenses by $74.1 million in 2022 vs.

Evofem Biosciences Reports Year-End 2022 Financial Results and Provides Corporate Update

SAN DIEGO , April 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment of Ivy Zhang as Chief Financial Officer (CFO) and Secretary, effective April 13, 2023. Reporting to Chief Executive Officer Saundra Pelletier, Ms.

Evofem Appoints Ivy Zhang as Chief Financial Officer and Secretary

SAN DIEGO, April 12, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced a major new win in New York state that improves coverage for Phexxi® (lactic acid, citric acid and potassium bitartrate), its hormone-free contraceptive vaginal gel, for more than 5.8 million lives statewide.

Evofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization Required

– Company cuts management pay and lowers headcount to decrease operating costs – – Reductions align with corporate goal to reach cash flow break even by year-end 2023 – SAN DIEGO , March 21, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) (the "Company") today announced it has implemented measures to lower its operating expenses, with the goal of reaching cash flow break even by year-end 2023. These measures include a 39% reduction of payroll expenses through a combination of: -  Salary cuts for certain employees, including a 40% reduction in Chief Executive Officer compensation and a 20% reduction in pay for other continuing members of the executive team vs.

Evofem Biosciences Announces Cost Reduction Measures

SAN DIEGO , March 9, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) is pleased to announce the appointment of Albert Altro as Interim Chief Financial Officer of the Company. He replaces Jay File, who is leaving the Company to explore other opportunities.

Evofem Biosciences Appoints Interim Chief Financial Officer

-- Phexxi is the first and only hormone-free contraceptive offered by reproductive telehealth leader SimpleHealth to its patients -- SAN DIEGO , Feb. 28, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that reproductive telehealth leader SimpleHealth now offers Phexxi® (lactic acid, citric acid and potassium bitartrate), the first and only hormone-free vaginal gel approved by the FDA for contraception. "This partnership with SimpleHealth will increase awareness of Phexxi and provide access to the only non-hormonal birth control women use on demand," said Saundra Pelletier, Chief Executive Officer of Evofem.

Evofem's Phexxi Contraceptive Gel Added to SimpleHealth Product Offering

-- Evofem now has four Orange Book listed patents covering Phexxi into 2033 --  SAN DIEGO , Feb. 27, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that two additional U.S. patents which cover  Phexxi®  (lactic acid, citric acid and potassium bitartrate) and its labeled indication are now listed in the U.S. Food and Drug Administration (FDA) publication  Approved Drug Products with Therapeutic Equivalence Evaluations , commonly known as the Orange Book . "The Orange Book listing of these two patents covering Phexxi's composition of matter and its method of use in contraception is an important step in further strengthening our patent portfolio," said Evofem Biosciences CEO Saundra Pelletier.

Evofem Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for Phexxi

SAN DIEGO , Feb. 23, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM), announced today that its Board of Directors has unanimously approved a comprehensive strategic process to explore and evaluate strategic alternatives to maximize shareholder value. Evofem is the provider of Phexxi, the first and only FDA-approved hormone-free, woman-controlled contraceptive gel that women use on demand.

Evofem Biosciences to Explore Strategic Alternatives to Maximize Shareholder Value

-- Phexxi is the first and only hormone-free contraceptive in the Favor product portfolio -- SAN DIEGO , Jan. 12, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that female telehealth leader Favor is now a specialty pharmacy provider of Phexxi® (lactic acid, citric acid and potassium bitartrate). Favor (formerly called The Pill Club) has added Phexxi to its product portfolio and will counsel patients on this hormone-free prescription contraceptive gel alongside the more than 120 hormonal options they currently offer.

Evofem's Phexxi Contraceptive Gel to be Offered by Female Telehealth Leader Favor (Formerly The Pill Club)

SAN DIEGO , Jan. 10, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that Phexxi ® (lactic acid, citric acid, potassium bitartrate) has been added to the Costco Member Prescription Program, giving millions of additional women access to this innovative hormone-free contraceptive. "We are pleased to partner with Costco, the largest warehouse club and third-largest retailer in America, to expand Phexxi's footprint in the cash space," said Saundra Pelletier, Chief Executive Officer of Evofem.

Costco Adds Phexxi® to Member Prescription Program

-- Medicaid improves Phexxi coverage for more than 3.7 million lives across 11 states -- -- Largest commercial insurer in Michigan and a marquis university plan in Pennsylvania move Phexxi to Preferred formulary position with $0 copay and no restrictions, affecting nearly 2.25 million lives in aggregate -- SAN DIEGO , Jan. 9, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced multiple new insurance wins that give millions of additional women access to Phexxi ® (lactic acid, citric acid, potassium bitartrate) for the hormone-free prevention of pregnancy. "Evofem's unrelenting focus and engagement with payers continues to deliver results, expanding and improving access to Phexxi for millions of women across the country," said Saundra Pelletier, Chief Executive Officer of Evofem.

Multiple New Insurance Wins Expand and Improve Access to Phexxi® for Millions of Women

SAN DIEGO , Dec. 29, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that it has been granted additional time by the OTC Markets Group to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the "10-Q").  Previously, the OTC Markets Group provided until December 29, 2022 to file the 10-Q.

OTC Markets Group Grants Evofem Additional Time to File Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2022

SAN DIEGO , Oct. 11, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the recently completed Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea infection in women did not achieve its endpoints. The product safety profile was consistent with what has been observed in prior clinical trials, and only two women (0.1%) in the study discontinued due to adverse events.

Evofem Reports Top-Line Results from Phase 3 EVOGUARD Clinical Trial Evaluating EVO100 for Prevention of Chlamydia and Gonorrhea Infection in Women

-- First Regulatory Approval Outside the U.S. -- SAN DIEGO , Oct. 6, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that its hormone-free contraceptive vaginal gel has been approved by the Nigerian Regulatory Agency NAFDAC (National Agency for Food and Drug Administration and Control).  This marks the Company's first approval outside the United States.

Evofem Biosciences Announces Approval of Phexxi in Nigeria

SAN DIEGO , Oct. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) announced today that the trading of its common shares has been upgraded to the OTCQB Venture Market from the OTC Pink Open Market. The Company's ticker symbol remains the same.

Evofem Biosciences Announces Uplisting to OTCQB

-- Issuance of U.S. Patent No. 11,439,610 Further Strengthens Evofem's Intellectual Patent Portfolio -- -- Newly Issued Patent Expected to Provide Protection for Phexxi into At Least 2033 -- SAN DIEGO , Sept.

Evofem Announces Issuance of U.S. Patent Covering Phexxi® Composition of Matter

-- Evofem Gains Forbearance from Debtholders for All Existing Matters-- SAN DIEGO , Sept. 16, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCPK: EVFM) today announced the successful restructuring of its debt, providing forbearance from its debtholders related to all existing events of default.

Evofem Announces Successful Debt Restructuring

-- Conference Call Scheduled for 5:00 p.m. ET -- SAN DIEGO , Aug. 10, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) will hold an investor call as follows: Date: Thursday, August 1 1, 2022 Time: 5:00 p.m.

Evofem Biosciences to Host Investor Call on Thursday, August 11, 2022

NEW YORK, NY / ACCESSWIRE / August 9, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Evofem Biosciences. Mark Roberts, Senior Editor at Traders News Source had the opportunity to conduct the interview featuring Saundra Pelletier, CEO of Evofem Biosciences.

Traders News Source Senior Editor, Mark Roberts Interviews Evofem Biosciences, Inc. CEO Saundra Pelletier

Athenex

American Virtual Cloud Technologies

Here's what you need to know about buying penny stocks on August 5th? The post Penny Stocks to Buy Premarket on August 5th?

Penny Stocks to Buy Premarket on August 5th? 3 to Watch

Evofem Biosciences, Inc. (NASDAQ:EVFM ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Amy Raskopf - Vice President-Investor Relations Saundra Pelletier - Chief Executive Officer, President and Executive Director Jay File - Chief Financial Officer Katherine Atkinson - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Yale Jen - Laidlaw and Company Stacy Lee - Stifel Ram Selvaraju - H.C. Wainwright Operator Good afternoon.

Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q2 2022 Results - Earnings Call Transcript

-- 42% growth in Phexxi® (lactic acid, citric acid and potassium bitartrate) net product sales quarter over quarter -- -- Reduced operating expense by 8% and improved loss from operations by 16% -- -- Completed registrational Phase 3 trial evaluating Phexxi for the prevention of chlamydia and gonorrhea; on track to report top-line data in October 2022 -- -- Conference call scheduled for 5:00 p.m. ET today -- SAN DIEGO , Aug. 4, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and six-month periods ended June 30, 2022 and affirmed full-year 2022 guidance.

Evofem Biosciences Announces Strong Second Quarter 2022 Financial Results and Affirms 2022 Guidance

SAN DIEGO , Aug. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Jenny Yip, a Managing Partner at life sciences investment fund Adjuvant Capital, to its Board of Directors. The appointment of Ms.

Evofem Biosciences Strengthens Board of Directors

Phoenix, Arizona--(Newsfile Corp. - August 1, 2022) - The Stock Day Podcast welcomed Evofem Biosciences (NASDAQ: EVFM) ("the Company"), an innovator in women's sexual and reproductive health and the maker of hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate). Evofem's CEO, Saundra Pelletier, joined Stock Day host Sever Copley. "What is Phexxi and how does it fit into the contraceptive landscape?" asked Copley.

Evofem Biosciences Discusses Innovative Woman-Controlled Contraceptive with The Stock Day Podcast

-- Top-line readout of data expected in October 2022 -- -- U.S. regulatory submission planned for the first half of 2023 -- -- Phexxi may become the first-ever woman-controlled prophylactic for the prevention of chlamydia and gonorrhea -- SAN DIEGO , Aug. 1, 2022  /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced that the last subject has completed her last visit in EVOGUARD, the Company's registrational Phase 3 trial evaluating the efficacy and safety of Phexxi® (lactic acid, citric acid, potassium bitartrate) for the prevention of chlamydia and gonorrhea infection in women. There are no prescription pharmaceuticals approved to prevent these sexually transmitted infections (STIs).

Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in Women

News for Evofem Biosciences Inc Stock (EVFM)